Amylyx Pharmaceuticals
AMLX
122 hedge funds and large institutions have $188M invested in Amylyx Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 35 increasing their positions, 40 reducing their positions, and 20 closing their positions.
65% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 20
34% more capital invested
Capital invested by funds: $141M → $188M (+$47.6M)
11% more funds holding
Funds holding: 110 → 122 (+12)
8.85% more ownership
Funds ownership: 63.82% → 72.67% (+8.8%)
13% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 40
30% less call options, than puts
Call options by funds: $1.36M | Put options by funds: $1.94M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$21.9M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$7.12M |
| 3 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$4.18M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$2.81M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$5.65M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$5.45M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$3.73M |
| 4 |
AWG
Alpha Wave Global
New York
|
-$2.45M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$2.17M |
AMLX Hedge Fund Activity: Q4 2024 in Review
122 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q4 2024, worth a combined $188M — up 34% from $141M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new AMLX positions and 20 closed out — a net gain of 13 holders — while 35 added to existing stakes and 40 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $21.9M. The largest seller was Alyeska Investment Group, cutting an estimated $5.65M.
- 122 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q4 2024, up from 110 in Q3 2024.
- Funds reported $188M of Amylyx Pharmaceuticals stock for Q4 2024, up 34% quarter-over-quarter.
- 33 funds opened new Amylyx Pharmaceuticals positions in Q4 2024 and 20 closed out, a net change of +13 holders.
- The largest Amylyx Pharmaceuticals buyer in Q4 2024 was Perceptive Advisors, an estimated $21.9M added.
- The largest Amylyx Pharmaceuticals seller in Q4 2024 was Alyeska Investment Group, an estimated $5.65M sold.
Based on aggregated 13F filings for Q4 2024.